Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Diffuse Large B-Cell Lymphoma With Combined TP53 mutation and MIR34A methylation: Another “double hit” Lymphoma With Very Poor Outcome?

Fazila Asmar, MD, Christoffer Hother, MD, PhD, Gorjan Kulosman, MD, Marianne B. Treppendahl, MD PhD, Helene Myrtue Nielsen, MSc, Ralfkiaer Ulrik, MSc, Anja Pedersen, Michael B. Møller, MD, DMSc, Elisabeth Ralfkiaer, MD, DMSc, Peter de Nully Brown, MD, Kirsten Grønbæk, MD, DMSc

Blood (2013) 122 (21): 83.

https://doi.org/10.1182/blood.V122.21.83.83

Published: 2013

Journal Articles

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Marianne B. Treppendahl, MD, Magnus Tobiasson, MD, Anni Aggerholm, PhD, Mohsen Karimi, PhD, Trine Silkjaer, MD, Lone S. Friis, MD, PhD, Mette K. Andersen, PhD, Lars Kjeldsen, MD, PhD, Mette S. Holm, MD, PhD, Eva Hellström-Lindberg, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 2394.

https://doi.org/10.1182/blood.V120.21.2394.2394

Published: 2012

Journal Articles

miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A , and MIR34B/C

Christoffer Hother, MD, Fazila Asmar, MD, Gorjan Kulosman, MD, Marianne B. Treppendahl, MD, Ditte Reker, Ulrik Ralfkiaer, MSc, Anja Pedersen, Michael B. Møller, MD, DMSc, Peter De Nully Brown, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 296.

https://doi.org/10.1182/blood.V120.21.296.296

Published: 2012

Journal Articles

Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML,

Marianne B. Treppendahl, MD, Xiangning Qiu, MD, Alexandra Søgaard, MSc, Cecilie Nandrup-Bus, MSc, Christoffer Hother, MD, Mette Klarskov Andersen, MD, Lars Kjeldsen, MD, PhD, Lars Möllgård, MD, Eva Hellstrom-Lindberg, MD, PhD, Johan Jendholm, MSc, Bo T. Porse, PhD, Peter A. Jones, PhD, DSc, Gangning Liang, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2011) 118 (21): 3450.

https://doi.org/10.1182/blood.V118.21.3450.3450

Published: 2011

Journal Articles

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Marianne B. Treppendahl, MD, Xiangning Qiu, MD, Christoffer Hother, MD, Mette K. Andersen, MD, PhD, Lars Kjeldsen, MD, PhD, Peter Jones, Professor, Gangning Liang, PhD, Kirsten Gr∅nbæk, MD, PhD

Blood (2010) 116 (21): 3629.

https://doi.org/10.1182/blood.V116.21.3629.3629

Published: 2010

NARROW

Diffuse Large B-Cell Lymphoma With Combined TP53 mutation and MIR34A methylation: Another “double hit” Lymphoma With Very Poor Outcome?

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A , and MIR34B/C

Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML,

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Email alerts

ASH Publications

American Society of Hematology

Diffuse Large B-Cell Lymphoma With Combined TP53 mutation and MIR34A methylation: Another “double hit” Lymphoma With Very Poor Outcome?

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A , and MIR34B/C

Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML,

Epigenetic Silencing of a Novel Candidate Tumor Suppressor “miR” Predicts Poor Prognosis In High-Risk MDS and AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only